If you have been reading about pentapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
==== Multiple bodies per grave ==== Some couples or groups of people (such as a married couple or other family members) may wish to be buried in the same plot. In some cases, the coffins (or urns) may simply be buried side by side. In others, one casket may be interred above another. If this is planned for in advance, the first casket may be buried more deeply than is the usual practice so that the second casket may be placed over it without disturbing the first. In many states in Australia all graves are designated two or three depth (depending on the water table) for multiple burials, at the discretion of the burial rights holder, with each new interment atop the previous coffin separated by a thin layer of earth. As such all graves are dug to greater depth for the initial burial than the traditional six feet to facilitate this practice. Mass burial is the practice of burying multiple bodies in one location. Civilizations attempting genocide often employ mass burial for victims. However, mass burial may in many cases be the only practical means of dealing with an overwhelming number of human remains, such as those resulting from a natural disaster, an act of terrorism, an epidemic, or an accident. This practice has become less common in the developed world with the advent of genetic testing, but even in the 21st century remains which are unidentifiable by current methods may be buried in a mass grave. Individuals who are buried at the expense of the local authorities and buried in potter's fields may be buried in mass graves.
Healthy diet (a diet with limited refined carbohydrates, added sugars, trans fats, as well as limited intake of sodium and total calories) Physical fitness (30–45 minutes of cardiovascular exercise per day, 3–5 days a week) Weight loss by as little as 5–10 percent may have a significant impact on overall health
== B == B-cell lymphoma – B cells – B lymphocytes (B cells) – bactericidal – bacteriostatic – bacterium – baculovirus – baseline – basophil – bDNA test – beta-2 microglobulin (β2M) – bilirubin – bioavailability – biological response modifiers (BRMs) – biopsy – biotechnology – blinded study – blips – blood–brain barrier – body fat redistribution (BFR) syndrome – body fluids – bone marrow – bone marrow suppression – booster – branched DNA assay – breakthrough infection – Broadway Cares/Equity Fights AIDS – bronchoscopy – budding – buffalo hump – bugchasing and giftgiving – Burkitt's lymphoma
Sources: en.wikipedia.org
FHA-HUD policy guaranteed that pay lenders would be compensated in full for the mortgage of foreclosed homes and by creating a housing market dominated by mortgage bankers, the FHA incentivized mortgage bankers to drive desperate black families to low-income homeownership, allowing bankers to inflate their economic gains by cycling these black families through tax foreclosures. Therefore, this racist and predatory provision of low-income housing through FHA-HUD policy elucidates that federal government was an inevitable perpetrator of racial segregation within Detroit's housing market. Despite having access to mortgage loans, black Detroiters continued to be preyed upon by real estate bankers who earned tremendous profits from the inability of black Detroiters to keep up with the FHA-insured mortgage payments. For many black Detroiters, the dismissal of FHA redlining did not end the economic exploitation and residential segregation of black families at the hands of wealth-hungry bankers and lenders. Colorblind universalism within Detroit's housing market remained a far-fetched aspiration of Black families in their pursuit of homeownership as FHA-HUD policy failed to dismantle the segregative impulses of the real estate industry. Furthermore, the threat of racial integration in white communities facilitated the rise of neighborhood associations, which were coalitions of independent white homeowners that fervently protected homeownership rights through advocacy for residential segregation.
=== Internal nasal anatomy === In the midline of the nose, the septum is a composite (osseo-cartilaginous) structure that divides the nose into two similar halves. The lateral nasal wall and the paranasal sinuses, the superior concha, the middle concha, and the inferior concha, form the corresponding passages, the superior meatus, the middle meatus, and the inferior meatus, on the lateral nasal wall. The superior meatus is the drainage area for the posterior ethmoid bone cells and the sphenoid sinus; the middle meatus provides drainage for the anterior ethmoid sinuses and for the maxillary and frontal sinuses; and the inferior meatus provides drainage for the nasolacrimal duct. The internal nasal valve comprises the area bounded by the upper lateral-cartilage, the septum, the nasal floor, and the anterior head of the inferior turbinate. In the narrow (leptorrhine) nose, this is the narrowest portion of the nasal airway. Generally, this area requires an angle greater than 15 degrees for unobstructed breathing; for the correction of such narrowness, the width of the nasal valve can be increased with spreader grafts and flaring sutures.
The four substrates of this enzyme are taxifolin, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are dihydrogossypetin, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is phenol,NADPH:oxygen oxidoreductase (2-hydroxylating). Other names in common use include phenol hydroxylase, and phenol o-hydroxylase. It uses flavin adenine dinucleotide as a second cofactor. The systematic name of this enzyme class is taxifolin,NAD(P)H:oxygen oxidoreductase (8-hydroxylating). This enzyme is also called taxifolin hydroxylase.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.